Antileishmanial activity of 1,3,4-thiadiazolium-2-aminide in mice infected with Leishmania amazonensis.
The efficacy of two mesoionic derivatives (MI-H-H and MI-4-OCH(3)) was evaluated in CBA/J mice infected with Leishmania amazonensis. Treatment with these compounds demonstrated that the MI-4-OCH(3) derivative and the reference drug meglumine antimoniate (Glucantime) presented significant activity relative to an untreated control. No apparent hepatic or renal toxicity due to these mesoionic compounds was found.
Rodrigues
Raquel F
RF
Instituto Oswaldo Cruz/Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
Charret
Karen S
KS
da Silva
Edson F
EF
Echevarria
Aurea
A
Amaral
Verônica F
VF
Leon
Leonor L
LL
Canto-Cavalheiro
Marilene M
MM
D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use* / Q000633:toxicity; D001772:Blood Cell Count; D007894:Leishmania mexicana; D016773:Leishmaniasis, Cutaneous / Q000097:blood / Q000188:drug therapy* / Q000523:psychology; D008198:Lymph Nodes / Q000469:parasitology; D008536:Meglumine / Q000009:adverse effects / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D051379:Mice; D008808:Mice, Inbred CBA; D009569:Nitric Oxide / Q000378:metabolism; D009942:Organometallic Compounds / Q000009:adverse effects / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D013830:Thiadiazoles / Q000627:therapeutic use* / Q000633:toxicity
C539945:1,3,4-thiadiazolium-2-aminide; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D013830:Thiadiazoles; D009569:Nitric Oxide; D008536:Meglumine; D000077485:Meglumine Antimoniate